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A B S T R A C T
Background: Intravascular ultrasound (IVUS) is the most widely used ancillary method in Interventional 
Cardiology, and its analysis depends on standards for acquisition, measurement and interpretation of the 
images. By associating tissue characterization, the artifact caused by the guidewire may overestimate the 
percentage of necrotic core in certain lesions, leading to misclassification of fibroatheroma. In this paper we 
described quantitative and tissue analysis effects resulting from subtracting the effect of guidewire artifact 
on atherosclerotic lesions in patients with acute coronary syndrome.
Methods: Twenty-one patients with post-thrombolysis myocardial infarction were evaluated with grayscale 
IVUS and iMAPTM technology, totaling 76 lesions.
Results: Grayscale IVUS showed that the lesions had a mean length of 21.01 ± 18.03 mm and revealed high 
plaque burden (52.07 ± 7.56%). The analysis by iMAPTM demonstrated that, after subtracting the guidewire 
artifact, there was a reduction of all tissue (necrotic, calcific, lipid and fibrotic) components, but more 
markedly in necrotic core (mean difference: 3.59%). In addition, after artifact subtraction 12.4% of the lesions 
that initially exhibited a necrotic core ≥ 10% ceased to be classified as fibroatheroma.
Conclusions: An atheroma analysis by iMAPTM technology showed that the guidewire artifact overestimated 
the tissue component of the necrotic core. This interference may change, in an erroneous and categorical way, 
the phenotypic characteristics of more stable and benign (fibrotic) lesions to potentially unstable lesions, for 
example, fibroatheromas, in a ratio of one out of ten patients.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Avaliação da subtração do artefato do fio-guia na análise quantitativa e tecidual 
com ultrassom intracoronário e tecnologia iMAP® em pacientes com síndrome 
coronária aguda: subanálise do estudo iWonder
R E S U M O
Introdução: O ultrassom intracoronário (USIC) é o método adjunto mais utilizado na Cardiologia 
Intervencionista, e sua análise depende da padronização para realização do procedimento e da 
interpretação das imagens. Ao associar a caracterização tecidual, o artefato causado pelo fio-guia pode 
hiperestimar o porcentual de núcleo necrótico em determinadas lesões, levando à classificação equivocada 
de fibroateroma. Descrevemos os efeitos quantitativos e na análise tecidual resultantes da subtração do 
efeito do artefato do fio-guia nas lesões ateroscleróticas em pacientes com síndrome coronária aguda.
Métodos: Foram avaliados 21 pacientes com infarto do miocárdio pós-trombólise com USIC em escala de 
cinzas e com a tecnologia iMAP®, totalizando 76 lesões.
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Resultados: O USIC em escala de cinzas mostrou que as lesões tinham extensão média de 21,01 ± 18,03 
mm e apresentavam elevada carga de placa (52,07 ± 7,56%). A análise pelo iMAP® demonstrou que, após a 
subtração do artefato do fio-guia, houve redução de todos os componentes teciduais (necrótico, calcífico, 
lipídico e fibrótico), porém de maneira mais acentuada do núcleo necrótico (diferença média de 3,59%). 
Além disso, após a subtração do artefato, 12,4% das lesões que inicialmente apresentavam núcleo necrótico 
≥ 10% passaram a não ser mais classificadas como fibroateroma.
Conclusões: A análise da placa de ateroma pela tecnologia iMAP® mostrou que o artefato do fio-guia 
superestimou o componente tecidual do núcleo necrótico. Essa interferência pode mudar errônea e 
categoricamente as características fenotípicas de lesões mais benignas e estáveis (fibróticas) para lesões 
potencialmente instáveis, como os fibroateromas, na relação de um em cada dez pacientes.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Intravascular ultrasound (IVUS) is one of the most often used ad-
junct methods in modern interventional cardiology. Although coro-
nary angiography remains the most important imaging method in 
the diagnosis of coronary artery disease (CAD), in recent decades 
IVUS has developed considerably, and has assumed a relevant role in 
the hemodynamics laboratory.
Although initially its analysis was based on individual and non-
uniform accounts,1,2 recently, several groups have been organized in an 
attempt to standardize the analysis and interpretation of ultrasound 
images, both by gray scale analysis3,4 and by tissue characterization 
with virtual histology (VHTM IVUS; Volcano Corporation, San Diego, 
USA) and iMAPTM technology (Boston Scientific, Santa Clara, USA).5 
With this standardization, much progress has been made in the use of 
IVUS in everyday clinical practice, mainly as a guide in complex percu-
taneous coronary interventions (PCIs),6,7 such as in bifurcation lesions, 
long lesions, PCIs of the left main coronary artery,8,9 and studies of pro-
gression and regression of atherosclerosis.10-12
Adding tissue characterization to data obtained by grayscale analy-
sis, by means of radio frequency analysis of ultrasound waves, it has 
become possible to identify the characteristics of fibroatheroma and its 
several subtypes,13 and of the vulnerable plaque, which is prone to rup-
ture and responsible for acute coronary events.14-17 Conceptually, among 
other criteria, such as thin fibrous cap (< 65 m) and positive arterial 
remodeling, the vulnerable plaque, also known as thin-cap fibroather-
oma, must have a large confluent necrotic core (≥ 10%), and maintain 
> 30% contact with the lumen, for at least three consecutive frames.
However, a major obstacle to the appropriate identification and 
especially the quantification of the necrotic core is the artifact 
caused by the guidewire, when iMAPTM technology is applied. The 
guidewire, consisting of material that is highly reflective of ultra-
sound waves (echo-reflector), generates an artifact similar to that 
generated by calcium, called an acoustic shadow.18 The iMAPTM tech-
nology, when detecting the signal resounded from the guidewire, 
interprets this signal as compatible with necrotic tissue and errone-
ously classifies the area of acoustic shadow as necrotic core. This fact 
ultimately causes an overestimation of the necrotic core quantity in 
a particular lesion.
This study aimed to describe the quantitative and tissue analysis 
effects resulting from subtraction of the guidewire artifact effect in 
atherosclerotic lesions of patients with acute coronary syndrome, by 
using IVUS with gray scale analysis and iMAPTM technology.
Methods
Patients and study design
From September 2011 to February 2012, 21 patients with clinical 
and electrocardiographic diagnosis of ST-segment elevation acute 
myocardial infarction (STEMI), totaling 76 lesions, were prospec-
tively included in the iWonder study. The study design has been pre-
viously described.19 In short, 100 patients with acute myocardial 
infarction were analyzed with IVUS of the three epicardial coronary 
arteries in grayscale and with iMAPTM regarding the phenotypic and 
tissue characteristics of the culprit and non-culprit lesions. The 
study was carried out at the Hemodynamics and Interventional Cardi-
ology Department of Hospital São Paulo, São Paulo (SP), and was pre-
viously approved by the Research Ethics Committee of the institution 
(project 0889/11, August 5, 2011) and identified at ClinicalTrials.gov 
under number NCT01437553. All patients or their legal representa-
tives were informed about the objectives and risks of the procedures 
related to the study and signed the informed consent before under-
going the diagnostic procedure.
IVUS procedure
Images were obtained by IVUS of the epicardial coronary arteries, 
which was performed immediately after the diagnostic procedure, 
under full heparinization (unfractionated heparin 100 U/kg, aiming 
an activated clotting time between 250 and 350 seconds) and intra-
coronary vasodilator administration (nitroglycerin 100-200 m). 
Initially, IVUS study of the artery related to the clinical event (culprit 
vessel) was performed, followed by angioplasty, if necessary. Next, 
the two other coronary arteries unrelated to the clinical event (non-
culprit vessels) were analyzed through IVUS. A 40 MHz IVUS cathe-
ter was used (AtlantisTM SR Pro; Boston Scientific, Santa Clara, USA), 
with grayscale analysis and morphological characterization using 
iMAP-Intravascular UltrasoundTM evaluation (iMAP-IVUSTM; Boston 
Scientific, Santa Clara, USA). Automatic pullbacks of the IVUS cathe-
ter were performed at a velocity of 0.5 mm/s, beginning at a point 
10 mm distal from the culprit lesion, toward the ostium of the artery 
being evaluated. In non-culprit arteries, the same routine was per-
formed to analyze plaques unrelated to the event.
Analysis of intravascular ultrasound images
All angiographic and IVUS images were stored in digital media 
and copied to an external hard drive for offline analysis in the Intra-
vascular Imaging Core Laboratory of the Cardiovascular Research 
Foundation (New York, USA).
The analysis of IVUS was performed in three sequential steps, as 
follows.
Step 1 – quantitative analysis
The quantitative volumetric analysis was performed according to 
current guidelines.3,4 This offline step of IVUS analysis consisted of 
the definition of the segment to be analyzed in each pullback, in-
cluding at least 10 mm in length distally to the ostium of the respec-
tive vessel. Then, using QIvusTM version 2.1 software (Medis Medical 
Imaging Systems, Leiden, The Netherlands), the automatic contours 
of the vessel and lumen were obtained at each 1 mm within the de-
fined segment. Then, using the Simpson method, the volumes of the 
54 C. F. Souza et al. / Rev Bras Cardiol Invasiva. 2015;23(1):52-57
lumen, vessel, and plaque (vessel less lumen) were computed. The 
plaque burden was calculated as the cross-sectional area of the 
plaque divided by the cross-sectional area of the vessel, multiplied 
by 100. Minimum luminal area was defined as the smallest cross-
sectional area of the lumen within the lesion.
Step 2 – tissue characterization by iMAPTM
IMAP-IVUSTM is an imaging modality that uses radiofrequency 
spectral analysis to obtain an algorithm used to classify the athero-
sclerotic plaque into four components: fibrotic, lipidic, necrotic, and 
calcific. The development of this algorithm was based on histologi-
cal analyses ex vivo20 and each component is assigned a color: 
fibrotic component as green, lipidic component as yellow, necrotic 
component as red, and calcific component as white.
Step 3 – subtraction of the guidewire artifact
After f inishing the contour of the vessel and lumen cross-
sectional areas, the measurements were exported to the appropriate 
database. Then, using the subtraction tool available in QIvus 2.1TM, 
the guidewire artifact was manually delimited by an experienced 
examiner (C.F.S.) in each frame of the segment defined as lesion 
(proximal and distal reference segments were excluded), as shown 
in Figure 1. The values obtained were then exported to the database 
for comparison with the initial measures.
Statistical analysis
In the descriptive statistical analysis, categorical variables were 
expressed as absolute and percentage frequency. Continuous vari-
ables were expressed as mean ± standard deviation. Paired t-test 
was used for comparison between the groups. The p-value was con-
sidered significant when < 0.05. To perform the analyses, SPSS ver-
sion 13.0 (SPSS Inc., Chicago, USA) was used.
Results
The mean age of patients was 53.3 ± 13.1 years, with a predomi-
nance of males (61.9%). The mean time between the index event and 
the performance of IVUS was 6.1 ± 2.4 days. Among the risk factors for 
CAD, the following were observed: high prevalence of diabetes (52.4%), 
systemic arterial hypertension (66.7%), and smoking (66.7%). The other 
clinical and angiographic characteristics are summarized in Table 1.
Using the grayscale analysis by IVUS (Table 2), culprit lesions 
with a mean length of 21.01 ± 18.03 mm and plaque volume of 
52.07% ± 7.56% were observed. The minimum luminal area was 3.89 
± 2.13 mm2, and plaque burden was 65.46% ± 14.20%.
It is important to observe the differences related to tissue compo-
sition by iMAPTM analysis (Fig. 2). After the subtraction of the guide-
wire artifact, there was a statistically significant reduction in the 
percentage of all components (necrotic, calcific, lipidic, and fibrotic; 
p < 0.001 for all). Furthermore, the only tissue component that 
showed mean relevant difference in the percentage pre- and post-
subtraction of the guidewire artifact was the necrotic core (differ-
ence of 3.59%), while the rest showed minimal variation (calcific 
component, 0.07%; lipidic, 0.52%; fibrotic, 0.98%).
Finally, as shown in Figure 3, using 10% necrotic core as a diagnos-
tic criterion for defining a lesion as a fibroatheroma, after the sub-
traction of the guidewire artifact, 12.4% of lesions that had showed 
necrotic core ≥ 10% ceased to be characterized as fibroatheromas.
Discussion
The present study evaluated 76 lesions in 21 patients with STEMI 
using IVUS with grayscale and tissue characterization with iMAPTM 
technology. The impact caused by the guidewire artifact on tissue 
composition of atherosclerotic plaques was defined. The main find-
Figure 1. Demonstration of the effect of guidewire artifact masking (A) in grayscale intravascular ultrasound; (B) tissue characterization with iMAPTM; observe the artifact caused 
by the guidewire at 4 o’clock, interpreted as necrotic core (red); (C) tissue characterization after masking of the guidewire artifact; (D and E) results by iMAPTM pre- and post-
masking of the guidewire artifact, showing necrotic core variation from 21.56 to 20.21%. 
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the tissue component that showed the most significant reduction 
was the necrotic component (difference 3.59%); due to subtraction of 
the guidewire artifact, 12.4% of the lesions that had previously 
shown a necrotic core ≥ 10% (meeting one of the criteria for fibroath-
eroma classification) were no longer classified as such.
The present study is the first to describe the effects of subtraction 
of the artifact caused by the guidewire in tissue characterization of 
CAD using iMAPTM technology. It is possible that the misinterpreta-
tion of the guidewire’s acoustic shadow as a necrotic core may lead 
to misclassification of a lesion still in the early stage of atherosclero-
sis as a fibroatheroma. Furthermore, the possibility of the guidewire 
overestimating the necrotic content can be even more pronounced 
in larger vessels and lesions with higher plaque burden.
As the ultrasound definition of f ibroatheroma involves the 
mandatory presence of ≥ 10% of confluent necrotic core,13 any arti-
fact that leads to erroneous increase in this component amount 
can result in misclassification. In a similar study using VH-IVUSTM, 
Table 1
Baseline clinical characteristics, laboratory tests, and drug therapy.
Variables n = 21
Age, years 53.3 ± 13.1
Male gender, n (%) 13 (61.9)
BMI, kg/m2 28.53 ± 6.56
Diabetes mellitus, n (%) 11 (52.4)
Systemic arterial hypertension, n (%) 14 (66.7)
Smoking, n (%) 14 (66.7)
Dyslipidemia, n (%) 8 (38.1)
Laboratory tests at admission
Total cholesterol, mg/dL 159.0 ± 42.5
HDL-c, mg/dL 34.5 ± 11.8
LDL-c, mg/dL 104.6 ± 34.5
Triglycerides, mg/dL 104.5 ± 40.0
Creatinine clearance, mL/kg 109.3 ± 53.1
High-sensitivity PCR, mg/L 14.2 ± 18.6
Fasting glycemia, mg/dL 132.6 ± 64.4
Glycated hemoglobin, % 7.03 ± 2.65
Culprit vessel, n (%)
Left anterior descending artery 7 (33.3)
Left circumflex artery 4 (19.0)
Right coronary artery 10 (47.6)
Medications at admission, n (%)
Acetylsalicylic acid 3 (14.3)
Thienopyridines 0 (0)
ACEI/ARB 11 (52.4)
Statins 7 (33.3)
Betablockers 8 (38.1)
Medications at hospital discharge, n (%)
Acetylsalicylic acid 21 (100)
Thienopyridines 21 (100)
ACEI/ARB 18 (85.7)
Statins 21 (100)
Betablockers 7 (33.3)
BMI: body mass index; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein 
cholesterol; PCR: C-reactive protein; ACEI/ARB: angiotensin-converting enzyme inhibitor/angioten-
sin-receptor blocker.
Table 2
Data from the grayscale intravascular ultrasound of the culprit lesion.
Variables
Pre artifact subtraction 
(n = 76)
Post artifact subtraction 
(n = 76) p-value
Grayscale analysis of the culprit lesion
Lesion extension, mm 21.01 ± 18.03 21.00 ± 18.04 0.66
Vessel volume, mm3 277.54 ± 271.64 277.52 ± 271.84 0.91
Lumen volume, mm3 123.67 ± 111.50 123.72 ± 111.76 0.65
Plaque volume, mm3 153.87 ± 162.96 153.80 ± 162.93 0.45
Plaque volume, % 52.07 ± 7.56 52.01 ± 7.59 0.20
Mean vessel area, mm3/mm 12.97± 4.17 12.97 ± 4.18 0.21
Mean lumen area, mm3/mm 6.13 ± 2.06 6.14 ± 2.06 0.13
Mean plaque area, mm3/mm 6.84 ± 2.59 6.83 ± 2.59 0.15
Grayscale analysis of the culprit lesion at MLA 
Vessel area at MLA, mm2 11.77 ± 4.45 11.77 ± 4.45 0.32
Lumen area at MLA, mm2 3.89 ± 2.13 3.90 ± 2.13 0.32
Plaque area at MLA, mm2 7.87 ± 3.77 7.87 ± 3.77 0.32
Plaque burden, % 65.46 ± 14.20 65.42 ± 14.24 0.32
iMAPTM tissue analysis by lesion
Necrotic component volume, mm3 39.96 ± 50.63 34.42 ± 44.82 < 0.001
Calcific component volume, mm3 4.29 ± 5.09 4.13 ± 4.90 < 0.001
Lipid component volume, mm3 11.68 ± 14.55 10.93 ± 13.81 < 0.001
Fibrotic component volume, mm3 97.93 ± 96.84 96.58 ± 95.62 < 0.001
Necrotic component volume, % 22.29 ± 9.38 18.7 ± 8.91 < 0.001
Calcific component volume, % 2.70± 1.71 2.62 ± 1.70 < 0.001
Lipid component volume, % 6.93 ± 1.85 6.41 ± 1.81 < 0.001
Fibrotic component volume, % 68.07 ± 10.85 67.09 ± 10.74 < 0.001
iMAPTM tissue analysis at MLA
Necrotic component volume, % 23.65 ± 13.55 20.17 ± 12.79 < 0.001
Calcific component volume, % 2.60 ± 2.58 2.46 ± 2.52 0.04
Lipid component volume, % 7.09 ± 3.03 6.59 ± 2.92 < 0.001
Fibrotic component volume, % 64.44 ± 17.57 63.15 ± 17.33 < 0.001
MLA: minimal luminal area.
Figure 2. Variation in the percentage of lesions with necrotic core (NC) ≥ 10% and 
< 10% before and after subtraction of the guidewire artifact.
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ings were as follows: after the subtraction of the guidewire artifact, 
there was a statistically significant reduction in all four tissue com-
ponents identified by iMAPTM (necrotic, calcific, lipidic, and fibrotic); 
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Sales et al.21 demonstrated that the artifact caused by the metallic 
stent struts, by reflecting the IVUS waves, produced an effect sim-
ilar to that of calcium. Therefore, with this type of technology, the 
artifact is interpreted as a calcific component. In 17 lesions treated 
with stent, these authors showed that, when comparing VH-IVUS 
before and after PCI, there was a statistically significant increase 
in the amount of the calcif ic component. However, they also 
showed that the necrotic component could be identified around 
the stent struts. As there was no proven association between PCI 
and the appearence of local necrotic tissue, the authors concluded 
that this finding was due to the artifact caused by the metallic 
stent struts.
Differently from VH-IVUSTM, iMAPTM technology identifies the 
guidewire artifact (acoustic shadow) as necrotic component (rather 
than calcific).22 In one of the present cases, a lesion that initially 
showed 43.21% necrotic component later showed 38.38%, after sub-
traction of the guidewire artifact. In this circumstance, there was no 
impact on the lesion phenotypic classification. However, it is possi-
ble that borderline lesions originally classified as fibroatheroma 
would be classified as more incipient forms of atherosclerosis after 
subtraction of the artifact, such as pathological intimal thickening or 
fibrotic plaque (both with necrotic core < 10%).
Limitations
The analysis of guidewire artifact subtraction was performed 
manually and may have under- or over-estimated tissue compo-
nents. The clinical applicability of iMAPTM technology and others 
that offer tissue diagnosis of the atheroma plaque is still a matter of 
debate, showing no support in clinical decision-making considering 
the current guidelines. The low spatial resolution of IVUS (approxi-
mately 200 m) may interfere with the design and calculation of 
vessel areas, mainly in the lumen area and, therefore, may have an 
impact on the percentage of each tissue component.
Conclusions
The analysis of atheroma plaque using iMAPTM technology in pa-
tients with STEMI showed that the guidewire artifact overestimated 
the necrotic core tissue component of the atherosclerotic plaque. 
This interference can categorically and erroneously alter the pheno-
typic characteristics of more benign and stable lesions (fibrotic) to 
potentially unstable lesions, such as atheromas, at a proportion of 
one in ten patients.
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